Q’Apel Names Haemonetics Exec Stewart Strong President, CEO

Q’Apel Medical, a company focused on neurovascular interventions, has named veteran medtech exec Stewart Strong as its new president and chief executive officer (CEO).

Strong touts more than 25 years of leadership experience in the medical device industry. He comes from Haemonetics, where he was global president of the Hospital Business Unit. There, he established a global commercial organization, launched innovative technologies, and successfully executed corporate strategies, collectively generating a threefold increase in revenue during his tenure.

He also previously served as president of the Teleflex Interventional business and was responsible for bolstering the company’s presence in the interventional cardiology and radiology spaces. Stewart Strong also had leadership positions at Vidacare (acquired by Teleflex in 2013) and AtriCure.

He’s also served on the board of directors of Vivasure Medical and Obvius Robotics.

“Stew is the right person at the right time to lead Q’Apel through our next phase of growth,” said R. King Nelson, Q’Apel’s Chairman of the Board. “He brings a passion for building and leading high-performing global teams and for developing commercial strategies to drive sustainable growth, which will serve him well as Q’Apel looks to accelerate our commercial performance in the U.S. and ramp up our global presence.”

“I am honored to assume this position and am excited to get started. Q’Apel is a leader in the neurovascular space, recognized for driving innovation and its customer-centricity,” said Strong. “I look forward to working with the Board of Directors, the executive leadership, and the global Q’Apel team to drive growth, shape our future, and to realize our full potential.”

In March 2023, the company earned a CE mark for its Walrus balloon guide catheter.